Bridge BioResearch Announces the Granting of US Patent for CD14
Bridge Bioresearch PLC (BBR) announces that the company has been granted the US patent for their CD14 molecule indicated for treatment of Diabetes Type 2, obesity, atherosclerosis as well as inflammatory diseases.
Originally acquired from the Spanish Biotech company Mellitus, BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule. BBR has now achieved the granting of the US patent, which according to Mr. Soren Stenderup, CEO of BBR, further strengthens the IP position of CD14 as this complements the already issued European patent.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Carl Zeiss Meditec affirms growth target for financial year 2009/2010, despite cautious start

Certain iron supplements may influence the development of colon cancer

Merck’s Acquisition of Sigma-Aldrich Receives Clearance from EU Regulators - Approvals Also Granted by Japan and China
ArGEN-X awarded €1.5 million IWT grant to advance the application of NHance Fc modifications in therapeutic antibodies
Active_ingredient
Bristol-Myers Squibb Names Karen Vousden to Board of Directors
